Sagespring Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Sagespring Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.62M	Buy	3,634 +47	+1%	+$21.9K	0.03%	223
2025 Q4	$1.63M	Buy	3,587 +657	+22%	+$283K	0.03%	220
2025 Q3	$1.15M	Sell	2,930 -255	-8%	-$107K	0.02%	277
2025 Q2	$1.42M	Sell	3,185 -45	-1%	-$20.7K	0.03%	217
2025 Q1	$1.57M	Buy	3,230 +934	+41%	+$435K	0.04%	182
2024 Q4	$925K	Buy	+2,296	New	+$1.06M	0.02%	233

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sagespring Wealth Partners's VRTX Position: Q1 2026 in Review

Sagespring Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q1 2026, buying an estimated $21.9K and bringing the position to 3,634 shares worth $1.62M. The position accounts for 0.03% of the portfolio, ranked #223.

Sagespring Wealth Partners first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.63M in Q4 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Sagespring Wealth Partners held 3,634 shares of Vertex Pharmaceuticals worth $1.62M as of Q1 2026.
Sagespring Wealth Partners bought 47 Vertex Pharmaceuticals shares in Q1 2026, an estimated $21.9K.
Vertex Pharmaceuticals made up 0.03% of Sagespring Wealth Partners's portfolio in Q1 2026, its #223 holding.
Sagespring Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Sagespring Wealth Partners's Vertex Pharmaceuticals position peaked at $1.63M in Q4 2025.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sagespring Wealth Partners's 13F filing for Q1 2026, filed 7 May 2026.